Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Insider Sells $138,600.00 in Stock

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Get Free Report) insider Gregory M. Weinhoff sold 10,000 shares of the business's stock in a transaction on Wednesday, June 25th. The shares were sold at an average price of $13.86, for a total transaction of $138,600.00. Following the completion of the transaction, the insider now owns 122,279 shares of the company's stock, valued at approximately $1,694,786.94. This represents a 7.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Centessa Pharmaceuticals Price Performance

Shares of CNTA traded up $0.09 during mid-day trading on Friday, hitting $13.13. 817,525 shares of the company were exchanged, compared to its average volume of 733,874. Centessa Pharmaceuticals PLC Sponsored ADR has a 1-year low of $8.46 and a 1-year high of $19.09. The company has a debt-to-equity ratio of 0.28, a quick ratio of 14.37 and a current ratio of 14.37. The company has a 50 day moving average of $12.83 and a 200-day moving average of $14.72. The stock has a market cap of $1.75 billion, a price-to-earnings ratio of -7.25 and a beta of 1.48.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.20) EPS for the quarter, beating analysts' consensus estimates of ($0.35) by $0.15. Analysts expect that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on CNTA shares. Chardan Capital began coverage on shares of Centessa Pharmaceuticals in a research note on Thursday, May 8th. They issued a "buy" rating and a $30.00 target price for the company. Needham & Company LLC assumed coverage on Centessa Pharmaceuticals in a research note on Wednesday, May 28th. They set a "buy" rating and a $35.00 target price for the company. Morgan Stanley reiterated an "overweight" rating and set a $27.00 target price on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Oppenheimer initiated coverage on shares of Centessa Pharmaceuticals in a report on Thursday, May 8th. They issued an "outperform" rating and a $6.00 price target for the company. Finally, Guggenheim reaffirmed a "buy" rating and set a $28.00 price objective on shares of Centessa Pharmaceuticals in a report on Wednesday, March 26th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $27.89.

Institutional Investors Weigh In On Centessa Pharmaceuticals

A number of hedge funds have recently modified their holdings of CNTA. JPMorgan Chase & Co. raised its position in shares of Centessa Pharmaceuticals by 40.1% in the fourth quarter. JPMorgan Chase & Co. now owns 190,385 shares of the company's stock valued at $3,189,000 after buying an additional 54,482 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Centessa Pharmaceuticals by 14.4% in the fourth quarter. Wellington Management Group LLP now owns 115,107 shares of the company's stock valued at $1,928,000 after buying an additional 14,494 shares during the last quarter. Franklin Resources Inc. raised its position in shares of Centessa Pharmaceuticals by 0.3% in the fourth quarter. Franklin Resources Inc. now owns 2,308,546 shares of the company's stock valued at $38,668,000 after buying an additional 6,000 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Centessa Pharmaceuticals by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 57,257 shares of the company's stock valued at $959,000 after buying an additional 660 shares during the last quarter. Finally, Trexquant Investment LP raised its position in shares of Centessa Pharmaceuticals by 52.8% in the fourth quarter. Trexquant Investment LP now owns 261,184 shares of the company's stock valued at $4,375,000 after buying an additional 90,233 shares during the last quarter. 82.01% of the stock is currently owned by institutional investors and hedge funds.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.